Mek Inhibitor (Dihydroxyprop-Diflu-Methoxyphen-Cyclopropa-Sulfami)


Indications and Reactions:

Role Indications Reactions
Secondary
Hepatic Neoplasm Malignant 10.0%
Prophylaxis 9.3%
Surgery 9.2%
Hypertension 8.0%
Medical Diet 6.7%
Decreased Appetite 5.4%
Abdominal Pain 5.2%
Hepatitis B 4.7%
Computerised Tomogram 4.6%
Diarrhoea 4.0%
Arthralgia 4.0%
Vomiting 3.6%
Gastric Ulcer 3.6%
Diabetes Mellitus 3.5%
Excoriation 3.5%
Constipation Prophylaxis 3.3%
Palmar-plantar Erythrodysaesthesia Syndrome 3.2%
Stomatitis 3.1%
Nuclear Magnetic Resonance Imaging 2.5%
Peripheral Sensory Neuropathy 2.4%
Arthralgia 13.8%
Duodenal Ulcer 13.6%
Retinal Vascular Thrombosis 11.9%
Left Ventricular Dysfunction 9.6%
Retinal Vascular Disorder 7.3%
Myopathy 5.9%
Hallucination 4.2%
Abdominal Pain 4.0%
Diarrhoea 4.0%
Upper Gastrointestinal Haemorrhage 3.8%
Cerebral Atrophy 3.6%
Cerebral Haemorrhage 3.3%
Aspartate Aminotransferase Increased 2.7%
Infectious Peritonitis 2.7%
Hepatic Failure 2.5%
Blood Bilirubin Increased 1.7%
Death 1.5%
Dyspnoea 1.3%
Neuromyopathy 1.3%
Subarachnoid Haemorrhage 1.3%

Drug Data